Pilar Teixidor-Rodríguez , Ferran Brugada-Bellsolà , Sebastián Menéndez-Girón , Luisa Parada-Arias , Cristina Hostalot-Panisello , Roser Garcia-Armengol , Sara Castañer-Llanes , Sílvia Comas-Anton , Marta Domenech-Viñolas , Cristina Carrato , Cristina Izquierdo , Jordi Busquets-Bonet , Carlos Javier Domínguez-Alonso , Eva Montané
{"title":"脑室周围胶质瘤：两个队列中与脑室开放相关的风险评估-一个前瞻性使用TachoSil®进行脑室封闭，另一个没有回顾性","authors":"Pilar Teixidor-Rodríguez , Ferran Brugada-Bellsolà , Sebastián Menéndez-Girón , Luisa Parada-Arias , Cristina Hostalot-Panisello , Roser Garcia-Armengol , Sara Castañer-Llanes , Sílvia Comas-Anton , Marta Domenech-Viñolas , Cristina Carrato , Cristina Izquierdo , Jordi Busquets-Bonet , Carlos Javier Domínguez-Alonso , Eva Montané","doi":"10.1016/j.ejso.2025.109670","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Historically, ventricular opening (VO) has been associated with a greater risk of postoperative complications and a risk of leptomeningeal spread (LMS) in periventricular gliomas especially high grade gliomas. There are no specific products on the market for ventricular sealing with registered studies. TachoSil® is widely used for supportive sealing of the dura mater. We wanted to assess the effectiveness and safety of TachoSil® as a ventricular sealant for periventricular gliomas surgery with VO.</div></div><div><h3>Methods</h3><div>A single-center, analytical, and observational study was conducted. Two cohorts of patients with gliomas and VO were compared. A prospective cohort treated with TachoSil® (2020–2024) and a retrospective control cohort without TachoSil® (2017–2023). We recorded epidemiological, clinical, radiological, and surgical variables and the percentage of complications attributable to the VO: CSF leak, pseudomeningocele, infection, hydrocephalus, or leptomeningeal spread (LMS).</div></div><div><h3>Results</h3><div>We included 68 patients: the prospective cohort treated with TachoSil® consisted of 37 patients and the control group of 31. The demographic, clinical, and radiologic characteristics of two cohorts were statistically homogeneous. Ventricular sealing with TachoSil® had wider resections (1.54cm3 ± SD 1.92 residual tumor volume vs. 3.71 cm3 ± SD 5.64, p = 0.032) and fewer postoperative complications related to VO (2 vs. 9 patients, p = 0.008).</div></div><div><h3>Conclusion</h3><div>This study demonstrates that the use of TachoSil® for sealing glioma patients with VO is safe and effective, reducing complications related to VO, increase the degree of resection and reduces readmissions and reinterventions resulting from complications arising from VO. A randomized clinical trial should be conducted.</div></div>","PeriodicalId":11522,"journal":{"name":"Ejso","volume":"51 6","pages":"Article 109670"},"PeriodicalIF":2.9000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Periventricular gliomas: Evaluation of the risks associated with ventricular opening in two cohorts—one prospective with TachoSil® for ventricular sealing and the other without it retrospective\",\"authors\":\"Pilar Teixidor-Rodríguez , Ferran Brugada-Bellsolà , Sebastián Menéndez-Girón , Luisa Parada-Arias , Cristina Hostalot-Panisello , Roser Garcia-Armengol , Sara Castañer-Llanes , Sílvia Comas-Anton , Marta Domenech-Viñolas , Cristina Carrato , Cristina Izquierdo , Jordi Busquets-Bonet , Carlos Javier Domínguez-Alonso , Eva Montané\",\"doi\":\"10.1016/j.ejso.2025.109670\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><div>Historically, ventricular opening (VO) has been associated with a greater risk of postoperative complications and a risk of leptomeningeal spread (LMS) in periventricular gliomas especially high grade gliomas. There are no specific products on the market for ventricular sealing with registered studies. TachoSil® is widely used for supportive sealing of the dura mater. We wanted to assess the effectiveness and safety of TachoSil® as a ventricular sealant for periventricular gliomas surgery with VO.</div></div><div><h3>Methods</h3><div>A single-center, analytical, and observational study was conducted. Two cohorts of patients with gliomas and VO were compared. A prospective cohort treated with TachoSil® (2020–2024) and a retrospective control cohort without TachoSil® (2017–2023). We recorded epidemiological, clinical, radiological, and surgical variables and the percentage of complications attributable to the VO: CSF leak, pseudomeningocele, infection, hydrocephalus, or leptomeningeal spread (LMS).</div></div><div><h3>Results</h3><div>We included 68 patients: the prospective cohort treated with TachoSil® consisted of 37 patients and the control group of 31. The demographic, clinical, and radiologic characteristics of two cohorts were statistically homogeneous. Ventricular sealing with TachoSil® had wider resections (1.54cm3 ± SD 1.92 residual tumor volume vs. 3.71 cm3 ± SD 5.64, p = 0.032) and fewer postoperative complications related to VO (2 vs. 9 patients, p = 0.008).</div></div><div><h3>Conclusion</h3><div>This study demonstrates that the use of TachoSil® for sealing glioma patients with VO is safe and effective, reducing complications related to VO, increase the degree of resection and reduces readmissions and reinterventions resulting from complications arising from VO. A randomized clinical trial should be conducted.</div></div>\",\"PeriodicalId\":11522,\"journal\":{\"name\":\"Ejso\",\"volume\":\"51 6\",\"pages\":\"Article 109670\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2025-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ejso\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0748798325000988\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/2/2 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ejso","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0748798325000988","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/2 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
从历史上看，脑室开放（VO）与脑室周围胶质瘤（尤其是高级别胶质瘤）术后并发症风险和脑膜轻散（LMS）风险相关。目前市场上还没有专门用于心室密封的产品。TachoSil®广泛用于硬脑膜的支持性密封。我们想评估TachoSil®作为脑室密封剂用于VO脑室周围胶质瘤手术的有效性和安全性。方法采用单中心、分析性、观察性研究。比较两组胶质瘤和VO患者。采用TachoSil®治疗的前瞻性队列（2020-2024）和不采用TachoSil®治疗的回顾性对照队列（2017-2023）。我们记录了流行病学、临床、放射学和外科变量以及由VO引起的并发症的百分比：脑脊液泄漏、假性脑膜膨出、感染、脑积水或脑脊膜扩散（LMS）。结果我们纳入了68例患者：接受TachoSil®治疗的前瞻性队列包括37例患者和31例对照组。两个队列的人口学、临床和放射学特征在统计学上是一致的。采用TachoSil®封堵脑室，切除范围更广（残余肿瘤体积1.54cm3±SD 1.92 vs. 3.71 cm3±SD 5.64, p = 0.032），与VO相关的术后并发症更少（2例vs. 9例，p = 0.008）。结论本研究表明，TachoSil®用于胶质瘤VO患者的封闭是安全有效的，可减少VO相关并发症，增加切除程度，减少VO并发症引起的再入院和再干预。应进行随机临床试验。
Periventricular gliomas: Evaluation of the risks associated with ventricular opening in two cohorts—one prospective with TachoSil® for ventricular sealing and the other without it retrospective
Introduction
Historically, ventricular opening (VO) has been associated with a greater risk of postoperative complications and a risk of leptomeningeal spread (LMS) in periventricular gliomas especially high grade gliomas. There are no specific products on the market for ventricular sealing with registered studies. TachoSil® is widely used for supportive sealing of the dura mater. We wanted to assess the effectiveness and safety of TachoSil® as a ventricular sealant for periventricular gliomas surgery with VO.
Methods
A single-center, analytical, and observational study was conducted. Two cohorts of patients with gliomas and VO were compared. A prospective cohort treated with TachoSil® (2020–2024) and a retrospective control cohort without TachoSil® (2017–2023). We recorded epidemiological, clinical, radiological, and surgical variables and the percentage of complications attributable to the VO: CSF leak, pseudomeningocele, infection, hydrocephalus, or leptomeningeal spread (LMS).
Results
We included 68 patients: the prospective cohort treated with TachoSil® consisted of 37 patients and the control group of 31. The demographic, clinical, and radiologic characteristics of two cohorts were statistically homogeneous. Ventricular sealing with TachoSil® had wider resections (1.54cm3 ± SD 1.92 residual tumor volume vs. 3.71 cm3 ± SD 5.64, p = 0.032) and fewer postoperative complications related to VO (2 vs. 9 patients, p = 0.008).
Conclusion
This study demonstrates that the use of TachoSil® for sealing glioma patients with VO is safe and effective, reducing complications related to VO, increase the degree of resection and reduces readmissions and reinterventions resulting from complications arising from VO. A randomized clinical trial should be conducted.
期刊介绍：
JSO - European Journal of Surgical Oncology ("the Journal of Cancer Surgery") is the Official Journal of the European Society of Surgical Oncology and BASO ~ the Association for Cancer Surgery.
The EJSO aims to advance surgical oncology research and practice through the publication of original research articles, review articles, editorials, debates and correspondence.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
